We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00907205
First Posted: May 22, 2009
Last Update Posted: June 13, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
SignalRX Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Semafore Pharmaceuticals